Zobrazeno 1 - 10
of 53
pro vyhledávání: '"Maria Catherine Pietanza"'
Autor:
Marina Chiara Garassino, Enriqueta Felip, Mark M. Awad, Wei Wang, Sung Jin Kim, Maria Catherine Pietanza, Delvys Rodriguez-Abreu
Publikováno v:
Journal of Clinical Oncology. 40:TPS9160-TPS9160
TPS9160 Background: Pembrolizumab (pembro) plus chemotherapy is a standard first-line treatment for patients with metastatic NSCLC without EGFR or ALK genomic alterations regardless of PD-L1 expression. The combination of pembro and vibostolimab, a h
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8c783f0d9076810ba14232a581080b85
https://doi.org/10.1200/jco.2022.40.16_suppl.tps9160
https://doi.org/10.1200/jco.2022.40.16_suppl.tps9160
Autor:
Maria Catherine Pietanza, Ke (Kirsten) Zu, Anne C. Deitz, Jennifer Uyei, Mike Liu, Arianna Nevo, Yuting Kuang, Darpan Darpan
Publikováno v:
Journal of Clinical Oncology. 39:e20592-e20592
e20592 Background: Concurrent chemoradiation (cCRT) has been the standard first line treatment for patients with limited-stage small cell lung cancer (LS-SCLC) for decades. Despite continued progress in refining chemotherapy and radiation modalities,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7665e651f24f62c85b5787767f3a65c3
https://doi.org/10.1200/jco.2021.39.15_suppl.e20592
https://doi.org/10.1200/jco.2021.39.15_suppl.e20592
Autor:
Anne C. Deitz, Ke (Kirsten) Zu, Mark Ayers, Jeanette Bæhr Georgsen, Maria Catherine Pietanza, Peter Meldgaard, Torben Steiniche
Publikováno v:
Zu, K K, Georgsen, J B, Meldgaard, P, Deitz, A, Ayers, M, Pietanza, M C & Steiniche, T 2021, ' Protein expression of programmed cell death ligand 1 and ligand 2 and their prognostic values in extensive-stage small cell lung cancer. ', Journal of Clinical Oncology, vol. 39, no. 15 suppl, pp. e20593-e20593 . https://doi.org/10.1200/JCO.2021.39.15_suppl.e20593
e20593 Background: The receptor-ligand interaction between programmed cell death protein-1 (PD-1) and its ligands (PD-L1 and PD-L2) plays a critical role in tumor immune evasion and has become a therapeutic target in a number of cancer types, includi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::779435e17d632916ef124ef78fedcda7
https://doi.org/10.1200/jco.2021.39.15_suppl.e20593
https://doi.org/10.1200/jco.2021.39.15_suppl.e20593
Autor:
Charles M. Rudin, Piro Lito, Lee M. Krug, Camelia S. Sima, Stephanie Smith-Marrone, Natasha Rekhtman, Inderpal S. Sarkaria, Maria Laureana Santos-Zabala, William D. Travis, Gregory J. Riely, Tunc Iyriboz, Afsheen Iqbal, Jarushka Naidoo, John J. Fiore, Maria Catherine Pietanza, Stephen Veach, Kaitlin M. Woo, Mark G. Kris
Publikováno v:
Clinical Lung Cancer. 17:e121-e129
Background Large cell neuroendocrine carcinoma (LCNEC) accounts for approximately 3% of lung cancers. Pathologic classification and optimal therapies are debated. We report the clinicopathologic features, treatment and survival of a series of patient
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5ca5ea5b5bbc4559d74806d9125da784
https://doi.org/10.1016/j.cllc.2016.01.003
https://doi.org/10.1016/j.cllc.2016.01.003
Autor:
Francisco Orlandi, Terufumi Kato, Mahmut Gumus, Gregory P. Kalemkerian, Yiwen Luo, Charles M. Rudin, Mark M. Awad, Solange Peters, Maria Catherine Pietanza, Parneet Cheema, Mira Wollner, Delvys Rodriguez-Abreu, Grzegorz Czyzewicz, Maya Gottfried, Tibor Csőszi, Hye Ryun Kim, James Chih-Hsin Yang, Alexander Luft, Julien Mazieres, Alejandro Navarro
Publikováno v:
Journal of Clinical Oncology. 38:9001-9001
9001 Background: Pembro monotherapy showed durable antitumor activity as third-line or later therapy for metastatic SCLC, leading to FDA approval in that setting. KEYNOTE-604 was a double-blind, phase 3 study of pembro + EP vs placebo + EP as first-l
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a9e29ebc9b83acba9ae9e90af3d95b9a
https://doi.org/10.1200/jco.2020.38.15_suppl.9001
https://doi.org/10.1200/jco.2020.38.15_suppl.9001
Publikováno v:
American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting. 38
Several factors play a role in job selection after completion of a hematology/oncology training program, such as a fellows’ overall career goals, expected income potential, and limitations imposed by visa status, among many others. Training program
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::18c15f80435e616608ad2f9324f5890b
https://pubmed.ncbi.nlm.nih.gov/30231402
https://pubmed.ncbi.nlm.nih.gov/30231402
Autor:
Matthew D. Hellmann, Shaozhou K. Tian, Natasha Rekhtman, Charles M. Rudin, Ronglai Shen, Nicholas D. Socci, Darragh Halpenny, Alexander Drilon, Anya Litvak, Michael F. Berger, Arshi Arora, William D. Travis, Helen Won, Maria Catherine Pietanza, Paul K. Paik, Jarushka Naidoo, Hangjun Wang, Marc Ladanyi, John T. Poirier, Andre L. Moreira
Purpose: Pulmonary large cell neuroendocrine carcinoma (LCNEC) is a highly aggressive neoplasm, whose biologic relationship to small cell lung carcinoma (SCLC) versus non-SCLC (NSCLC) remains unclear, contributing to uncertainty regarding optimal cli
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1274d2f2aa7a41c48f9c6ef24fb5f65b
https://europepmc.org/articles/PMC4995776/
https://europepmc.org/articles/PMC4995776/
Autor:
Junting Zheng, Sara A. Hayes, Mark G. Kris, Michelle S. Ginsberg, D. O’Driscoll, Chaya S. Moskowitz, Maria Catherine Pietanza
Purpose To examine the correlations between uni-dimensional RECIST and volumetric measurements in patients with lung adenocarcinoma and to assess their association with overall survival (OS) and progression-free survival (PFS). Materials and methods
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d5a414aa33fe724763b3f1a5055f935e
https://europepmc.org/articles/PMC4750046/
https://europepmc.org/articles/PMC4750046/
Autor:
Libor Havel, Martin Reck, David R. Spigel, Aleksandra Szczesna, Teresa Sanchez, Sang We Kim, Paul Lorigan, J. Fairchild, Kazuhiko Nakagawa, Michael Thomas, Yi-Long Wu, Anne Pieters, Christoph C. Zielinski, Alexander Luft, Wallace Akerley, Maria Catherine Pietanza, Leora Horn, Joachim G.J.V. Aerts, Kathryn A. Gold, Enriqueta Felip
Publikováno v:
Journal of Clinical Oncology, 34(31), 3740-+. American Society of Clinical Oncology
Europe PubMed Central
Europe PubMed Central
Purpose Patients with extensive-stage disease small-cell lung cancer (SCLC) have poor survival outcomes despite first-line chemotherapy with etoposide and platinum. This randomized, double-blind phase III study evaluated the efficacy and safety of ip
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::33422fcfad4240e726a78a0df7ba7ec9
https://pure.eur.nl/en/publications/116017bb-e1ce-4d1a-a62f-33b501e3e0a1
https://pure.eur.nl/en/publications/116017bb-e1ce-4d1a-a62f-33b501e3e0a1
Publikováno v:
Current Problems in Cancer. 36:156-173
Thirty thousand patients are diagnosed with small cell lung cancer (SCLC) in the United States each year [1]. Tobacco exposure is strongly associated with the development of this disease. SCLC has a unique natural history with a much shorter doubling
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1a4b91fcd2634b51787779ff09536283
https://doi.org/10.1016/j.currproblcancer.2012.03.005
https://doi.org/10.1016/j.currproblcancer.2012.03.005